Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2021 | NERO trial: PARP inhibitors for chemosensitive NSCLC

Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, shares an update on the randomized Phase II/III NERO study (NCT01788332) investigating PARP inhibitors in patients with non-small cell lung cancer (NSCLC) who have previously responded to chemotherapy. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.